In Japan, placenta injections are prescription drugs, not wellness supplements. The two placenta extract injections approved for sale in Japan are Laennec (ラエンネック) and Melsmon (メルスモン). Both are classified as prescription drugs and as "specified biological products," so they are used only on a doctor's prescription. Laennec is approved to improve liver function in chronic liver disease; Melsmon is approved for menopausal symptoms and insufficient breast milk production.
The blood donation rule changed in 2026. From October 10, 2006, Japan deferred anyone who had ever received these injections from giving blood, with no time limit. From October 1, 2026, the Japanese Red Cross Society instead asks people not to donate for 3 months after their last injection; after 3 months they can donate. The often-repeated claim that a placenta injection bars you from giving blood for life no longer reflects the current rule.
The two injections: ingredients, approved uses and dosing
Based on the electronic package inserts published by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and the manufacturer's product information:
| Laennec | Melsmon | |
|---|---|---|
| Regulatory status | Prescription drug; specified biological product | Prescription drug; specified biological product |
| Active ingredient | Water-soluble substances from enzymatically digested human placenta; 112 mg per 2 mL ampoule | Water-soluble substances from broken-down human placental villi; 100 mg per 2 mL ampoule |
| Approved indication | Improving liver function in chronic liver disease | Menopausal symptoms; insufficient lactation |
| Dosing | Adults usually 2 mL once a day by subcutaneous or intramuscular injection, up to 2–3 times a day depending on symptoms | Usually 2 mL once a day, daily or every other day, by subcutaneous injection only |
| On the market since | Sales began July 1974 | Approved as a drug in October 1956 |
A few points are worth noting:
- The approved uses are narrow. Right after its indication, Laennec's package insert adds a reminder that the indication is improving liver function in chronic liver disease and that the drug should be used appropriately with that in mind. The MHLW's October 2026 Q&A likewise states that insurance covers the two drugs for their approved indications: menopausal symptoms and insufficient lactation for Melsmon, and liver function in chronic liver disease for Laennec.
- Melsmon's indications were once broader. According to the manufacturer's interview form, before a 1983 drug re-evaluation Melsmon's indications also included fatigue, recovery after illness or surgery, and anemia. The re-evaluation narrowed them to the current two.
- These are extracts, not cells. The active ingredients are water-soluble substances obtained by breaking down placental tissue, and Laennec is heat-sterilized at 121°C for 20 minutes during manufacturing. They are a different category from stem cell or NK cell treatments, which clinics provide after filing a plan under the Act on the Safety of Regenerative Medicine. See Regenerative Medicine in Japan: How the Safety Act Works and the Three Risk Classes.
What official documents say about cosmetic use
When the MHLW announced the blood donation deferral in August 2006, it listed the two drugs' indications and then noted that these injections are also known to be used in part for cosmetic purposes, such as age spots, wrinkles and acne. That is the direct official statement on cosmetic use.
Two other facts sit alongside it: insurance covers the two drugs for their approved indications, and Laennec's package insert asks that it be used appropriately in light of its approved indication. For how Japan divides insured care from self-pay care in general, see Why Regenerative Treatment in Japan Is Self-Pay.
Injections and oral placenta supplements are different things in Japan
Besides injections, "placenta" is sold as capsules, drinks and other oral products. In Japan, whether an ingredient can be used in food or only in medicines is set by the MHLW's food-versus-drug classification lists, and here the source of the placenta decides it:

- Human placenta is classified as a medicine-only ingredient. Products containing it are treated as drugs.
- Bovine, ovine and porcine placenta are on the list of ingredients that are not judged to be drugs as long as the product makes no drug-like claims, so they can be used as food ingredients.
So in Japan, animal placenta can go into food, on condition that the product doesn't claim drug-like effects, while human placenta stays in the drug category.
| Injections (Laennec, Melsmon) | Oral placenta products | |
|---|---|---|
| Source | Human placenta | Animal placenta such as bovine, ovine or porcine |
| Status | Prescription drug; specified biological product | Food, provided no drug-like claims are made |
| How it is used | Prescribed by a doctor and injected at a medical institution | Bought by consumers |
Blood donation: why the deferral began and what it is now
From 2006: an open-ended deferral
On August 23, 2006, a safety committee of the blood program subcommittee of Japan's Pharmaceutical Affairs and Food Sanitation Council agreed that the Japanese Red Cross Society should defer blood donors who had used human placenta extract injections. The MHLW explained the reasoning:
- There had been no reported case of variant Creutzfeldt-Jakob disease (vCJD) linked to these injections.
- But like transfusions and organ transplants, they are made from human tissue, so a theoretical risk of vCJD transmission could not be ruled out.
- As a precaution, users would be screened out at the pre-donation interview.
The deferral began on October 10, 2006, and applied to anyone who had ever used these injections, with no time limit. Until October 2026, the Red Cross donor questionnaire asked specifically whether you had received Laennec or Melsmon.
From October 1, 2026: three months after the last injection
On January 14, 2026, the safety committee concluded that lifting the restriction was appropriate, after weighing vCJD trends in Japan and abroad, an MHLW-funded assessment of infection risk, and donor policies in other countries. Then:
- On September 14, 2026, the Japanese Red Cross Society announced new donor criteria from October 1, 2026: people who have used Laennec or Melsmon should not donate for 3 months after their last injection, and can donate once 3 months have passed.
- The MHLW's Q&A explains that placenta injection users now fall under the Red Cross's general rule for specified biological products: a 3-month deferral after administration.
In other words, the 3-month wait was not created specifically for placenta injections. It applies because they are specified biological products, handled the same way as others in that group.
One timing point: Melsmon's manufacturer interview form, dated December 2023, still says users are asked to avoid donating blood. That wording predates the new rule; the Red Cross criteria in effect from October 1, 2026 now govern donation in Japan. The donor interview's other screening questions still apply, and eligibility is decided at the interview on the day.
If you live in the United States or elsewhere and donate there, your local blood service applies its own screening questions. Tell the staff about any injections you received in Japan and follow their criteria.
What the package inserts warn about
Both inserts put the human-placenta origin at the center of their precautions:

- Infection risk cannot be ruled out entirely. Laennec's insert opens by stating that, because the drug is made from human placenta, the risk of transmitting infection cannot be completely excluded, so the need for treatment should be weighed carefully and use kept to the minimum necessary. The placentas come from full-term normal deliveries in Japan and pass donor interviews, blood tests and nucleic acid testing (NAT). The heat sterilization inactivates many viruses, but the insert also states that a virus below the NAT detection limit could still be present.
- Theoretical vCJD risk. Both inserts state that there have been no reports of vCJD transmission from the drug, but the theoretical risk cannot be completely excluded, and patients should be given a full explanation.
- Side effects. Both list shock (frequency unknown) as a serious adverse reaction. Laennec also lists injection-site pain and hardening; allergic reactions such as rash, fever and itching; breast enlargement in men; and abnormal liver function and headache. Melsmon lists injection-site pain and redness, and allergic reactions such as chills, nausea, fever, flushing and rash.
- Records kept for 20 years. Because these are specified biological products, the medical institution must record the drug name, lot number, date of use and the patient's name and address, and keep the record for at least 20 years, so users can be traced if a problem linked to the source material ever comes to light.
Looking at anti-aging options beyond placenta
Many people who ask about placenta injections are really asking about anti-aging. Options in Japan range from lifestyle and supplements to stem cell and NK cell treatments provided under filed plans, and exosomes, each with a different regulatory status and level of evidence. See Stem Cell Therapy for Anti-Aging: Evidence, Risks and What Shapes the Cost and Exosome Therapy.

Healthy adults interested in anti-aging can ask us directly. Our advisors work directly with Japanese hospitals and clinics, match you with a suitable doctor and hospital, and arrange medical record translation, a remote video consultation, interpretation during your visit and follow-up after you return home. Consultation and coordination are free; you can start with our pre-screening. If you have used placenta injections or other drugs, mention them so the doctor can take them into account. If you have a chronic condition, take regular medication, or are pregnant or planning a pregnancy, a Japanese doctor first needs to review your medical records.
Frequently asked questions
Are placenta injections in Japan a drug or a supplement?
A drug. Laennec and Melsmon are prescription drugs and specified biological products, used only on a doctor's prescription. In Japan, human placenta is a medicine-only ingredient; only animal placenta can be used in food.
Can I donate blood after a placenta injection?
Yes, after 3 months. Under the Japanese Red Cross criteria in effect from October 1, 2026, you should not donate for 3 months after your last injection and can donate once 3 months have passed. The earlier open-ended deferral has been lifted.
Why were placenta injection users barred from donating in the first place?
As a precaution. No case of vCJD had been linked to these injections, but because they are made from human placenta, a theoretical risk of transmission could not be ruled out, so donors were screened out from 2006.
What are Laennec and Melsmon approved for?
Laennec is approved to improve liver function in chronic liver disease, and Melsmon for menopausal symptoms and insufficient lactation; insurance covers them for their approved indications. An MHLW document from 2006 notes that these injections are also used in part for cosmetic purposes.
Does the clinic keep a record of my injection?
Yes. Both drugs are specified biological products, so the medical institution records the drug name, lot number, date and your name and address, and keeps the record for at least 20 years.
Sources: PMDA electronic package inserts for Laennec (revised January 2026, 2nd edition) and Melsmon (revised December 2023, 9th edition); Melsmon Pharmaceutical, Melsmon drug interview form (December 2023); MHLW press release on blood donation deferral for human placenta extract injection users (August 24, 2006); MHLW Q&A on the review of blood donation deferrals for overseas stays and placenta injection use (October 2026); MHLW Blood and Blood Products Division notice (September 15, 2026); Japanese Red Cross Society press release (September 14, 2026) and Transfusion Information Annual Report 2024; MHLW food-versus-drug ingredient classification lists (revised May 2026). Checked November 2026; MHLW, PMDA and Japanese Red Cross Society publications prevail.
Medical disclaimer: This site provides general information only and does not constitute medical advice; whether any treatment is suitable for you must be decided by a doctor after an in-person consultation.